Dysregulation of lipid metabolism plays a key role in development and progression of metabolic disorders including obesity, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD). Our group's overall goal is understand lipid metabolism in human and to develop novel approaches for deep metabolic phenotyping. To this end, we are developing several approaches including state-of-the-art lipidomics/metabolomics and metabolic modelling to understand lipid metabolism and its regulation. This would allow better characterization and stratification of patients during disease progress and in response to a given treatment. Ultimately, leading to interventions that could improve metabolism, and thus could potentially prevent the onset of many common human diseases associated with dyslipidemia and unresolved inflammation.
- Prof. Dr. Annalisa Berzigotti (University Clinic for Visceral Surgery and Medicine, University Hospital Bern)
- Prof. Dr. Jaume Bosch (University for Visceral Surgery and Medicine, University Hospital Bern)
- Prof. Dr. Reino Wiest (University for Visceral Surgery and Medicin, University Hospital Bern)
- Prof. Dr. Lia Bally (University Clinic for Diabetology and Endocrinology, University Hospital Bern)
- Prof. Dr. Guido Beldi (University Clinic for Visceral Surgery and Medicine, University Hospital Bern)
- Prof. Dr. Nadia Mercader Huber (Institute of Anatomy, University of Bern)
- Spatial Omics consortium, Bern
Our research is funded by Swiss National Science Foundation and the Innovative medicines Initiative 2. The LITMUS project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No. 777377. This Joint Undertaking receives support from the Euorpean Union's Horizon 2020 research and innovation programme and EFPIA.